

iZafe Group invites shareholders and other stakeholders to a Q&A session in connection with the publication of the first quarter report

iZafe Group AB (publ) - announces that in connection with the interim report for the first quarter of 2022, which will be published at 08:30 CET on April 29, 2022, shareholders, media, and other stakeholders will be given the opportunity to ask questions to the company.

The questions will be answered by CEO Anders Segerström and published on iZafe Group's investor page on May 9, 2022, under the heading financial reports, investor questions.

Please send your questions to ir@izafegroup.com before 10:00 CET (10 a.m.) on May 4, 2022.

Contacts

Anders Segerström, Chief Executive Officer E-mail: anders.segerstrom@izafegroup.com

Phone number: +46 70-875 14 12

iZafe Group AB (publ.) Södra Fiskartorpsvägen 20 114 33 Stockholm

E-mail: <u>ir@izafegroup.com</u> www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company's digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: info@fnca.se. Further information is available at www.izafe.se/investor-relations/.



Attachments

<u>iZafe Group invites shareholders and other stakeholders to a Q&A session in connection with the publication of the first quarter report</u>